Skip Navigation LinksHome > May 1991 - Volume 74 - Issue 5 > Sodium Nitroprusside Infusion Does Not Dilate Cerebral Resis...
Anesthesiology:
CLINICAL INVESTIGATIONS: PDF Only

Sodium Nitroprusside Infusion Does Not Dilate Cerebral Resistance Vessels during Hypothermic Cardiopulmonary Bypass.

Rogers, Anne T. M.B.Ch.B., F.R.C.P.(C); Prough, Donald S. M.D.; Gravlee, Glenn P. M.D.; Roy, Raymond C. M.D., Ph.D.; Mills, Stephen A. M.D., CM; Stump, David A. Ph.D.; Phipps, Julia R.N.; Royster, Roger L. M.D.; Taylor, Carol L. M.A.S.

Collapse Box

Abstract

This study determined whether sodium nitroprusside (SNP) changes cerebral vascular resistance during stable, hypothermic cardiopulmonary bypass (CPB). Cerebral blood flow (CBF) was measured using Xenon clearance in 39 patients anesthetized with fentanyl. In 25 patients (group 1), CBF was measured before and during infusion of SNP at a rate sufficient to reduce mean arterial pressure (MAP) ~ 20%. In 14 other patients (group 2), CBF was measured before and during simultaneous infusion of SNP and phenylephrine; SNP was continued at a rate that had reduced MAP ~ 20% while phenylephrine was added in a dose sufficient to restore MAP to preinfusion levels. Patients within each group were randomized to maintenance of PaCO2 ~ 40 mmHg (groups la and 2a), uncorrected for body temperature, or to maintenance of PaCO2 ~ 50 mmHg (groups 1b and 2b). The following variables were maintained within a narrow range: nasopharyngeal temperature (26-29[degrees] C), pump oxygenator flow (1.7-2.5 1[middle dot]min-1 [middle dot]m-2), PaO2 (150-300 mmHg), and Hct (22-28 vol%). In each patient, controlled variables varied no more than +/-5% between measurements. In group la (PaCO2 ~ 40 mmHg), MAP was 86 +/- 9 mmHg (mean +/- SD) before and 65 +/- 8 mmHg during SNP infusion (P < 0.0001). CBF was 12 +/- 3 ml [middle dot] 100 g-1 [middle dot] min-1 before and 10 +/- 2 ml[middle dot]100-1 min-1 during SNP infusion (P < 0.01). In group 1b (PaCO2 ~ 55 mmHg), MAP was 86 +/- 11 mmHg before and 66 +/- 13 mmHg during SNP infusion (P < 0.0001). CBF changed from 22 +/- 10 to 16 +/- 6 ml +/- 100 g-1 [middle dot] min-1 (P < 0.05). In group 2a (PaCO2 ~ 40 mmHg), MAP was 71 +/- 10 mmHg before and 73 +/- 9 mmHg during the combined SNP-phenylephrine infusion (P = not significant). CBF was 12 +/- 2 ml [middle dot] 100 g-1 min-1 before and 10 +/- 1 ml [middle dot] 100 g-1 [middle dot] min-1 during the combined infusion (P < 0.05). In group 2b (PaCO2 ~ 50 mmHg), MAP was 74 +/- 8 mmHg before and 71 +/- 4 mmHg during the combined infusion (P = ns). CBF was 18 +/- 5 ml [middle dot] 100 g-1 min-1 before and 15 +/- 5 ml [middle dot] 100 g-1 min-1 during the combined infusion (P < 0.01). The decrease in CBF was statistically similar in each group and was comparable to that previously reported to occur as a function of the duration of stable hypothermic CPB. Restoration of MAP by phenylephrine during continued SNP infusion did not result in either a relative or absolute CBF increase. During nonpulsatile, hypothermic CPB, SNP does not produce primary cerebral vasodilation in humans anesthetized with fentanyl.
(C) 1991 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.